Epithalon

• Weeks 1-3: Your 10-20 day course; effects build slowly
• After the course: Course over; studies saw melatonin rise after it
• Months 1-3 off: Break; no shots. Notice how you sleep
• Months 3-6 off: Next course 3-6 months after the last one ends
• Side effects: Usually none; stop for allergy signs or a new lump

More on each stage

Weeks 1-3

This is your course: one shot each evening for 10 days (or up to 20, into week 3). Some community users report better sleep within weeks. Guides describe the effects as slow and gradual.

After the course

The course is over. In the small human studies, night-time melatonin rose after a 10-20 day course in people whose melatonin was low to start with.

Months 1-3 off

You are in your break. There is nothing to inject. The research tradition says benefits build over repeated courses across years, not from one course. Notice how you sleep off it.

Months 3-6 off

Still on break. The next course comes 3-6 months after the last one ends, so the earliest restart is about 3 months after your last shot. Start with a fresh vial.

Side effects

Usually none, or mild redness where you inject. Stop and get help for any sign of an allergic reaction. Stop and see a doctor if you notice a new lump, unexplained weight loss, or bleeding that will not stop.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• Raised low melatonin in older people

  Human study

  In small Russian studies, older people with low melatonin made more of it at night after a 10-day course of Epithalon shots. In a placebo-controlled study of 40 women aged 40-50 with low melatonin (mostly night-shift workers), 20 days of Epithalon under the tongue raised a urine marker of melatonin 1.7-fold.5631

• Better retina function in an inherited eye disease

  Human study

  In a Russian study of 162 people with retinitis pigmentosa (an inherited disease that slowly damages the retina), Epithalon shots next to the eye for 10 days improved retina function, with a positive effect reported in about 90% of cases.743

• Longer chromosome tips in lab cells

  Animal/lab study

  In lab dishes, Epithalon switched on telomerase and lengthened telomeres (the protective tips of chromosomes) in human cells. A 2025 UK study repeated this in normal cells. In breast cancer cells it lengthened telomeres through a different route. The FDA flags telomerase activation as a possible cancer concern.910

• Longest-lived mice lived longer

  Animal/lab study

  In female mice given Epithalon 5 days a month for life, the longest-lived 10% lived 13% longer, and leukemia was 6 times less common. Old monkeys made more evening melatonin. These are animal results only.118

• Better sleep and well-being (user reports)

  Community report

  Some users report better sleep, energy, or well-being within weeks of a course. Guides describe the effects as slow and gradual.1413

What it has been studied for

• Low melatonin in older people and night-shift workers. This is the closest human evidence for insomnia, which is the use the July 2026 compounding vote covered.5612Human study
• Retinitis pigmentosa (inherited retina disease). The FDA gave it orphan drug status for this in 2010, then withdrew it in 2016.71Human study
• Healthy aging and lifespan1193Animal/lab study

Epithalon is a tiny peptide made of just four building blocks (amino acids). Scientists built it to copy an extract from the pineal gland, a small gland in the brain that makes melatonin, the sleep hormone. In studies, it seems to nudge the pineal gland to make more melatonin at night when levels have fallen with age. In lab cells, it also switches on telomerase, a helper that rebuilds the protective tips on the ends of chromosomes, a bit like the plastic tips on shoelaces. Exactly how it works in the body is still unknown.

Peak

Not established in humans. The FDA found no human or animal studies measuring Epithalon in the blood after a shot.

Half-life

Not established in humans. No measurement has been published. Short peptides like this are usually broken down quickly in the body, but no number exists. Treat any half-life figure you see online with caution.

Cleared

Not established. The only data: in pregnant rabbits, a glowing-labeled form showed up in organs one hour after an IV dose. The FDA notes the signal may not have been Epithalon itself.

Half-life is how long it takes the body to remove half of a dose.143

Once a day. Evening, before bed. This is the store and community habit, tied to melatonin's night rhythm. The original Russian courses did not set a time of day. Every day for one short course of 10-20 days, then stop for 3-6 months. Units are for a 50 mg vial mixed with 2 mL water (25 mg per mL).

• Lower end · longer, smaller course

  5 mg once daily for about 20 days

  A common reading of the original Khavinson course: a smaller daily amount spread over more days. Not an approved dose.1314

• Most common · usual short course

  5-10 mg once daily for 10-20 days

  The range those write-ups treat as the standard short course, repeated only a couple of times a year.1314

• Community and clinic courses

  5-10 mg under the skin once a day for 10-20 days, repeated 1 to 4 times a year with 3-6 months between courses. Common versions: 5 mg a day for 20 days, or 10 mg a day for 10 days. Some clinics use 1-2 mg a day continuously.13141

Research protocols

• Older people with low melatonin

  0.01 mg a day injected into the muscle for 10 days (0.1 mg for the whole course).53

• Women aged 40-50 with low melatonin, placebo-controlled

  0.5 mg a day as a spray under the tongue (3 sprays twice a day) for 20 days.61

• Retinitis pigmentosa

  5 micrograms (0.005 mg) per eye, injected next to the eye, once a day for 10 days.743

• Mouse lifespan study

  1 microgram per mouse (about 30-40 micrograms per kg) under the skin on 5 days in a row each month, for life.11

Epithalon is not an approved medicine. The course lengths come from the Khavinson research tradition and later clinic write-ups, not from a large independent trial. The price here is for one vial. Vial sizes vary, so a full course can take more than one vial.

Dosing guidance built from the cited research and community reports. It is not a prescription.

On

10-20 days

Break

3-6 months

A full course at the store pace takes 1–2 vials. A mixed vial keeps for up to 90 days.

Why the break helps

Epithalon was always studied in short bursts: 10-20 day courses in people, and 5 days a month in a mouse lifespan study. Nobody has tested nonstop use. The FDA warns that Epithalon switches on telomerase (the enzyme that rebuilds chromosome tips) in lab cells, and that steady, long-term exposure could in theory help cells grow out of control. The long break keeps you close to the short courses that were studied and limits exposure to a peptide with no long-term human safety data. Most people run 1 or 2 courses a year.

Common

• Redness or mild soreness where you inject

  What to do Usually fades within a day. Move to a new spot each day. Check your technique and use a fresh needle every time.

• Mild change in sleep timing

  What to do Keep the shot at the same evening time each day. If your sleep gets worse, stop the course.

Stop and get help

• Signs of an allergic reaction: hives, itching all over, swelling of the face, lips or tongue, or trouble breathing

  What to do Stop Epithalon. Call 911 or go to the emergency room for swelling or trouble breathing.

• A new lump, unexplained weight loss, fevers that keep coming back, or bleeding that will not stop

  What to do Stop Epithalon and see a doctor soon. Because Epithalon switches on telomerase, it should not be used while any cancer question is open.

• An injection spot that gets hot, swollen, very painful, or has red streaks, especially with a fever

  What to do This can be an infection. Stop injecting and see a doctor the same day.

Do not use if

• You have cancer now or have had it, because Epithalon switches on telomerase and the FDA flags a possible cancer risk
• You are pregnant, trying to get pregnant, or breastfeeding: there are no safety data
• You are under 18
• You have had an allergic reaction to Epithalon before

Sources1

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), upright and away from light. Do not freeze it, and never leave it in a hot car.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.5 mL (50-unit) U-100 insulin syringe.

1. Check your vial label first. These numbers assume a 50 mg vial. If yours says a different amount, the units below do not apply.
2. Every 1 unit on a U-100 insulin syringe holds 0.25 mg. Draw to the 20-unit line for 5 mg, or the 40-unit line for 10 mg.
3. Before every draw, hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
4. Pinch a fold of skin, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out.
5. Use a new sterile syringe every time and never share one. Do not use the vial if the liquid turns cloudy or has specks in it.

• Thymosin Alpha-1

  Russian researchers paired a pineal-gland peptide with a thymus-gland peptide for older people, on the idea that both glands decline with age. In their long-term study, people given both extracts had lower death rates than controls. Those were the extracts Epithalamin and Thymalin, not Epithalon or thymosin alpha-1. Wellness clinics now combine Epithalon with thymosin alpha-1, but no study has tested this pair.1214

Interactions

• Melatonin supplements and sleep medicines

  Epithalon may raise your own melatonin, so effects could add up. This has not been studied.

  What to do Tell your doctor before combining them. Do not stop a prescribed sleep medicine on your own.

• Cancer treatment of any kind

  Epithalon switches on telomerase in lab cells, and its effect on cancer in people is unknown.

  What to do Do not use Epithalon during cancer treatment.

• Other new peptides started at the same time

  No drug-interaction studies exist. If you start two at once and something goes wrong, you cannot tell which one caused it.

  What to do Start one new peptide at a time, a week or more apart.

Sources

1. 1FDA briefing document on Epitalon, Pharmacy Compounding Advisory Committee, July 23-24, 2026Reference
2. 2RAPS: FDA advisory committee votes 7-5 to recommend Epitalon for the compounding list (July 2026)Reference
3. 3Jain et al., Epitalon and Epithalamin: a narrative review, Int J Mol Sci 2026Review
4. 4Araj et al., Overview of Epitalon, Int J Mol Sci 2025Review
5. 5Korkushko et al., Pineal peptides and the daily melatonin rhythm in old monkeys and elderly people, Adv Gerontol 2007Study
6. 6Ivko et al., AEDG peptide (Epithalon) and body-clock genes in people with low melatonin, Adv Gerontol 2020Clinical trial
7. 7Khavinson et al., Epitalon improves the retina in retinitis pigmentosa, Neuro Endocrinol Lett 2002Study
8. 8Goncharova et al., Epithalon and melatonin and cortisol in old monkeys, Bull Exp Biol Med 2001Study
9. 9Khavinson et al., Epithalon induces telomerase activity in human cells, Bull Exp Biol Med 2003Study
10. 10Al-Dulaimi et al., Epitalon increases telomere length in human cell lines, Biogerontology 2025Study
11. 11Anisimov et al., Epitalon, lifespan and tumors in female SHR mice, Biogerontology 2003Study
12. 12Khavinson and Morozov, Peptides of pineal gland and thymus prolong human life, Neuro Endocrinol Lett 2003Study
13. 13Peptidepedia: Epithalon dosage protocolsCommunity
14. 14TrimRX: Epithalon dosing protocol and cycling (clinic guide)Practitioner

Where people discuss it

• r/Peptides (subreddit)
• Peptidepedia — Epithalon dosage

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented